August 10, 2020 Mustang Bio Reports Second Quarter 2020 Financial Results and Recent Corporate Highlights
May 12, 2020 Mustang Bio Announces Presentations at 23rd Annual Meeting of the American Society of Gene & Cell Therapy
May 11, 2020 Mustang Bio Reports First Quarter 2020 Financial Results and Recent Corporate Highlights
April 20, 2020 Mustang Bio Receives Advanced Therapy Medicinal Product Classification from European Medicines Agency for MB-107 Lentiviral Gene Therapy for X-Linked Severe Combined Immunodeficiency
February 18, 2020 Mustang Bio Announces First Subject Treated in Phase 1/2 Trial with the Optimized CD20-targeted CAR T Cell Therapy MB-106